Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than Placebo
Benzinga · 06/12 07:03
Share
Listen to the news
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile —
—The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies —
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved